Springtide

In November 2020, Springtide announced a Series A financing of $18.1 million. Springtide is an an interdisciplinary multi-site practice treating children with autism spectrum disorder. The Company’s in-center care experience provides a coordinated, tech-enabled wrap-around for families who want their children to get all of their care in one setting.

Olema Pharmaceuticals

In October 2020, Olema Pharmaceuticals announced a Series C Preferred stock financing of $85 million. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast and gynecologic cancers.

Curation Health

In October 2020, Curation Health announced a Series A round financing. Curation Health is a clinical decision support platform designed to assist providers and health plans in navigating the transition from fee-for-service to value-based care. 

Sema4

In July 2020, Sema4 announced its Series C financing of $121 million. Sema4 is a patient-centered health intelligence company founded on the idea that more information, analysis, and engagement may improve the diagnosis, treatment, and prevention of disease.

Reprieve Cardiovascular

In July 2020, Reprieve Cardiovascular completed a Series A round financing of $15 million. Reprieve Cardiovascular is a medical device company focused on automated fluid management technologies for acute heart failure treatment.  

Liquid Wire

In July 2020, Liquid Wire announced a Series A round financing of $10 million. The Company is focused on developing and manufacturing flexible wiring and components to enable electronic circuitry in wearables to be used in multiple healthcare applications, as well as industrial (including safety). These applications typically involve dynamic environmental forces, such as changing temperature, movement, and humidity while maintaining reliable and consistent conductivity.

Annexon Biosciences

In July 2020, Annexon Biosciences announced a Series C round financing of $100 million. Annexon Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of therapies for patients with complement-mediated autoimmune and neurodegenerative disorders. 

Somatus

In June 2020, Somatus announced a Series C round financing of $64 million. Focused on value-based kidney care, Somatus partners with leading health plans, health systems, and nephrology and primary care groups to provide integrated care for patients with or at risk of developing kidney disease.

ARTMS

In May 2020, ARTMS announced a Series A round financing of $19 million. ARTMS develops and commercializes diagnostic imaging isotopes, utilizing hospital and other medical cyclotrons. The Company’s technology enables cost-effective, decentralized, and local production of medical isotopes.

LetsGetChecked

In May 2020, LetsGetChecked announced a Series C round financing of $70 million. LetsGetChecked is a health insights company that allows consumers direct access to a wide range of testing options and clinical services from home. By combining health data and diagnostic results, LetsGetChecked provides rich health insights to enable better healthcare decision-making, empowering people to take an active role in their health.